Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience.

Nanni L, Pellegrini C, Stefoni V, Argnani L, Cavo M, Zinzani PL.

Clin Lymphoma Myeloma Leuk. 2019 Aug 30. pii: S2152-2650(19)31251-0. doi: 10.1016/j.clml.2019.07.443. [Epub ahead of print] No abstract available.

PMID:
31543370
2.

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.

Ferrero S, Rossi D, Rinaldi A, Bruscaggin A, Spina V, Eskelund CW, Evangelista A, Moia R, Kwee I, Dahl C, Di Rocco A, Stefoni V, Diop F, Favini C, Ghione P, Mahmoud AM, Schipani M, Kolstad A, Barbero D, Novero D, Paulli M, Zamò A, Jerkeman M, Gomez da Silva M, Santoro A, Molinari A, Ferreri A, Grønbæk K, Piccin A, Cortelazzo S, Bertoni F, Ladetto M, Gaidano G.

Haematologica. 2019 Sep 19. pii: haematol.2018.214056. doi: 10.3324/haematol.2018.214056. [Epub ahead of print]

3.

BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia.

Broccoli A, Bertuzzi C, Fiorentino M, Morigi A, Stefoni V, Agostinelli C, Argnani L, Cavo M, Zinzani PL.

Onco Targets Ther. 2019 Jun 20;12:4807-4812. doi: 10.2147/OTT.S202061. eCollection 2019.

4.

Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial.

Zanoni L, Broccoli A, Lambertini A, Pellegrini C, Stefoni V, Lodi F, Fonti C, Nanni C, Zinzani PL, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1661-1671. doi: 10.1007/s00259-019-04323-6. Epub 2019 May 17.

PMID:
31102000
5.

Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience.

Marangon M, Stefoni V, Castellino A, Visco C, Tani M, Cox MC, Marasca R, Tecchio C, Devizzi L, Monaco F, Romano A, Rusconi C, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e321-e323. doi: 10.1016/j.clml.2019.03.020. Epub 2019 Mar 29. No abstract available.

PMID:
31080169
6.

PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series.

Casadei B, Broccoli A, Stefoni V, Pellegrini C, Marangon M, Morigi A, Nanni L, Lolli G, Carella M, Argnani L, Cavo M, Zinzani PL.

Haematologica. 2019 Mar 19. pii: haematol.2019.215962. doi: 10.3324/haematol.2019.215962. [Epub ahead of print]

7.

A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies.

Nanni L, Morigi A, Casadei B, Broccoli A, Stefoni V, Argnani L, Cavo M, Zinzani PL.

Hematol Oncol. 2019 Apr;37(2):202-204. doi: 10.1002/hon.2573. Epub 2019 Jan 30.

PMID:
30637815
8.

The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience.

Marangon M, Tonialini L, Morigi A, Stefoni V, Broccoli A, Pellegrini C, Casadei B, Argnani L, Cavo M, Zinzani PL.

Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25152. [Epub ahead of print] No abstract available.

9.

A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report.

Broccoli A, Nanni L, Stefoni V, Agostinelli C, Argnani L, Cavo M, Zinzani PL.

BMC Cancer. 2018 Jun 8;18(1):645. doi: 10.1186/s12885-018-4561-9.

10.

Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).

Stefoni V, Pellegrini C, Broccoli A, Baldini L, Tani M, Cencini E, Figuera A, Ansuinelli M, Bernocco E, Cantonetti M, Cox MC, Ballerini F, Rusconi C, Visco C, Arcaini L, Fama A, Marasca R, Volpetti S, Castellino A, Califano C, Cavaliere M, Gini G, Liberati AM, Musuraca G, Lucania A, Ricciuti G, Argnani L, Zinzani PL.

Oncologist. 2018 Sep;23(9):1033-1038. doi: 10.1634/theoncologist.2017-0597. Epub 2018 Apr 19.

11.

Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience.

Stefoni V, Broccoli A, Argnani L, Sabattini E, Cavo M, Zinzani PL.

Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):297-299. doi: 10.1016/j.clml.2018.02.007. Epub 2018 Feb 16. No abstract available.

PMID:
29500149
12.

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.

Pellegrini C, Broccoli A, Pulsoni A, Rigacci L, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Santoro A, Hoaus S, Rigolin GM, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Ronconi F, Gritti G, Vallisa D, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Bianchi MP, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Oncotarget. 2017 May 23;8(53):91703-91710. doi: 10.18632/oncotarget.18114. eCollection 2017 Oct 31.

13.

Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.

Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Carlo-Stella C, Hohaus S, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Gravetti A, Gritti G, Arcari A, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Naso V, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Storti S, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Haematologica. 2017 Nov;102(11):1931-1935. doi: 10.3324/haematol.2017.171355. Epub 2017 Aug 3.

14.

The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients.

Broccoli A, Casadei B, Stefoni V, Pellegrini C, Quirini F, Tonialini L, Morigi A, Marangon M, Argnani L, Zinzani PL.

BMC Cancer. 2017 Apr 17;17(1):276. doi: 10.1186/s12885-017-3269-6.

15.

Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis.

Broccoli A, Argnani L, Stefoni V, Gandolfi L, Zinzani PL.

Hematol Oncol. 2018 Feb;36(1):136-143. doi: 10.1002/hon.2412. Epub 2017 Mar 23.

PMID:
28332724
16.

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial.

Zinzani PL, Pellegrini C, Chiappella A, Di Rocco A, Salvi F, Cabras MG, Argnani L, Stefoni V.

Blood. 2017 Apr 20;129(16):2328-2330. doi: 10.1182/blood-2017-01-764258. Epub 2017 Mar 6. No abstract available.

PMID:
28264798
17.

Two cases of primary vitreoretinal lymphoma: a diagnostic challenge : The supporting role of multimodal imaging in the diagnosis of primary vitreoretinal lymphoma.

Morara M, Foschi F, Veronese C, Torrazza C, Bacci F, Stefoni V, Ciardella PA.

Int Ophthalmol. 2018 Feb;38(1):353-361. doi: 10.1007/s10792-016-0422-1. Epub 2016 Dec 30.

PMID:
28039672
18.

Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.

Gandolfi L, Pellegrini C, Casadei B, Stefoni V, Broccoli A, Tonialini L, Morigi A, Argnani L, Zinzani PL.

Oncologist. 2016 Dec;21(12):1436-1441. Epub 2016 Aug 2.

19.

Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results.

Stefoni V, Casadei B, Bottelli C, Gaidano G, Ciochetto C, Cabras MG, Ansuinelli M, Argnani L, Broccoli A, Gandolfi L, Pellegrini C, Zinzani PL.

Blood Cancer J. 2016 May 13;6:e425. doi: 10.1038/bcj.2016.29.

20.

90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.

Casadei B, Pellegrini C, Pulsoni A, Annechini G, De Renzo A, Stefoni V, Broccoli A, Gandolfi L, Quirini F, Tonialini L, Morigi A, Argnani L, Zinzani PL.

Cancer Med. 2016 Jun;5(6):1093-7. doi: 10.1002/cam4.684. Epub 2016 Mar 14.

21.

High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience.

Derenzini E, Stefoni V, Pellegrini C, Gandolfi L, Broccoli A, Casadei B, Quirini F, Argnani L, Tonialini L, Zinzani PL.

BMC Cancer. 2015 Nov 9;15:879. doi: 10.1186/s12885-015-1903-8.

22.

The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).

Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, Balzarotti M, Stelitano C, Spina M, Vitolo U, Stefoni V, Levis A, Gotti M, Rosaria S, Maria SP, Bosi A, Gallamini A.

Am J Hematol. 2015 Jun;90(6):499-503. doi: 10.1002/ajh.23994. Epub 2015 May 10.

23.

The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients.

Zinzani PL, Broccoli A, Casadei B, Stefoni V, Pellegrini C, Gandolfi L, Maglie R, Argnani L, Pileri S, Fanti S.

Hematol Oncol. 2015 Dec;33(4):145-50. doi: 10.1002/hon.2172. Epub 2014 Sep 25. Erratum in: Hematol Oncol. 2016 Jun;34(2):117.

PMID:
25256959
24.

Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.

Zinzani PL, Pellegrini C, Broccoli A, Gandolfi L, Stefoni V, Casadei B, Maglie R, Argnani L, Pileri S.

Hematol Oncol. 2015 Sep;33(3):141-6. doi: 10.1002/hon.2151. Epub 2014 Jul 2.

PMID:
24986783
25.

Role of autologous stem cell transplantation in T-cell lymphoma patients: a single institution retrospective analysis.

Stefoni V, Broccoli A, Argnani L, Maglie R, Pellegrini C, Gandolfi L, Zinzani PL.

Hematol Oncol. 2015 Sep;33(3):164-5. doi: 10.1002/hon.2145. Epub 2014 Jun 10. No abstract available.

PMID:
24916168
26.

Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine.

Pellegrini C, Stefoni V, Casadei B, Maglie R, Argnani L, Zinzani PL.

Ann Hematol. 2014 Nov;93(11):1853-7. doi: 10.1007/s00277-014-2121-1. Epub 2014 Jun 8.

PMID:
24908331
27.

Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma.

Pellegrini C, Argnani L, Broccoli A, Stefoni V, Derenzini E, Gandolfi L, Casadei B, Maglie R, Pileri S, Zinzani PL.

Oncologist. 2014 Jul;19(7):746-50. doi: 10.1634/theoncologist.2013-0463. Epub 2014 May 28.

28.

Is it really possible to cure hairy cell leukemia patients only with frontline therapy?

Zinzani PL, Stefoni V, Broccoli A, Pellegrini C, Gandolfi L, Casadei B, Maglie R, Pileri S, Argnani L.

Ann Hematol. 2014 Sep;93(9):1565-9. doi: 10.1007/s00277-014-2081-5. Epub 2014 Apr 22.

PMID:
24752417
29.

Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma.

Derenzini E, Stefoni V, Maglie R, Casadei B, Pellegrini C, Broccoli A, Stefani G, Fanti S, Motta MR, Narducci R, Argnani L, Zinzani PL.

Biol Blood Marrow Transplant. 2013 Dec;19(12):1695-701. doi: 10.1016/j.bbmt.2013.09.004. Epub 2013 Sep 18.

30.

Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens.

Zinzani PL, Pellegrini C, Gandolfi L, Casadei B, Derenzini E, Broccoli A, Quirini F, Argnani L, Pileri S, Celli M, Fanti S, Poletti V, Stefoni V, Baccarani M.

Hematol Oncol. 2013 Dec;31(4):183-8. doi: 10.1002/hon.2039. Epub 2012 Dec 5.

PMID:
23212941
31.

Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients.

Broccoli A, Stanzani M, Bandini G, Bonifazi F, Stefoni V, Pellegrini C, Derenzini E, Gandolfi L, Quirini F, Argnani L, Tschon M, Casadei B, Baccarani M, Zinzani PL.

Leuk Lymphoma. 2013 Aug;54(8):1791-3. doi: 10.3109/10428194.2012.749470. Epub 2012 Dec 22. No abstract available.

PMID:
23153229
32.

Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.

Zinzani PL, Pellegrini C, Merla E, Ballerini F, Fabbri A, Guarini A, Pavone V, Quintini G, Puccini B, Vigliotti ML, Stefoni V, Derenzini E, Broccoli A, Gandolfi L, Quirini F, Casadei B, Argnani L, Baccarani M.

Hematol Oncol. 2013 Dec;31(4):179-82. doi: 10.1002/hon.2036. Epub 2012 Oct 29.

PMID:
23108928
33.

Persistent agmination of lymphomatoid papulosis: an ongoing debate.

Pileri A, Bacci F, Neri I, Ciabatti S, Stefoni V, Zinzani PL, Patrizi A.

Dermatology. 2012;225(2):131-4. doi: 10.1159/000342201. Epub 2012 Sep 14. Review.

PMID:
22986223
34.

Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients.

Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, Vaggelli L, Zanoni L, Argnani L, Baccarani M, Fanti S.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):4-12. doi: 10.1007/s00259-011-1916-8. Epub 2011 Sep 6.

PMID:
21894546
35.

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.

Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M.

Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):462-6. doi: 10.1016/j.clml.2011.02.001. Epub 2011 May 4.

PMID:
21859554
36.

Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients.

Pellegrini C, Gandolfi L, Quirini F, Ruggieri P, Stefoni V, Derenzini E, Broccoli A, Argnani L, Pileri S, Mercuri M, Baccarani M, Zinzani PL.

Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):321-5. doi: 10.1016/j.clml.2011.03.021. Epub 2011 May 7.

PMID:
21816370
37.

Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature.

Broccoli A, Stefoni V, Faccioli L, Agostinelli C, Spinardi L, Pastore Trossello M, Zinzani PL.

Rheumatol Int. 2012 Jul;32(7):2209-13. doi: 10.1007/s00296-011-1998-4. Epub 2011 Jul 23. Review.

PMID:
21785962
38.

A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.

Zinzani PL, Tani M, Pulsoni A, De Renzo A, Stefoni V, Broccoli A, Montini GC, Fina M, Pellegrini C, Gandolfi L, Cavalieri E, Torelli F, Scopinaro F, Argnani L, Quirini F, Derenzini E, Rossi M, Pileri S, Fanti S, Baccarani M.

Ann Oncol. 2012 Feb;23(2):415-20. doi: 10.1093/annonc/mdr145. Epub 2011 May 2.

PMID:
21536660
39.

Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified.

Zinzani PL, Pellegrini C, Broccoli A, Stefoni V, Gandolfi L, Quirini F, Argnani L, Berti E, Derenzini E, Pileri S, Baccarani M.

Leuk Lymphoma. 2011 Aug;52(8):1585-8. doi: 10.3109/10428194.2011.573031. Epub 2011 Apr 19. No abstract available.

PMID:
21504290
40.

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.

Zinzani PL, Gandolfi L, Broccoli A, Argnani L, Fanti S, Pellegrini C, Stefoni V, Derenzini E, Quirini F, Baccarani M.

Cancer. 2011 Mar 1;117(5):1010-8. doi: 10.1002/cncr.25579. Epub 2010 Oct 19.

41.

FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma.

Lopci E, Santi I, Tani M, Maffione AM, Montini G, Castellucci P, Stefoni V, Rubello D, Fonti C, Zinzani P, Fanti S.

Q J Nucl Med Mol Imaging. 2010 Aug;54(4):436-41. Epub 2010 May 27.

PMID:
20823812
42.

Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.

Zinzani PL, Broccoli A, Stefoni V, Musuraca G, Abruzzese E, De Renzo A, Cantonetti M, Bacci F, Baccarani M, Pileri SA.

Cancer. 2010 Dec 15;116(24):5667-75. doi: 10.1002/cncr.25307. Epub 2010 Aug 24.

43.

Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.

Zinzani PL, Gandolfi L, Stefoni V, Fanti S, Fina M, Pellegrini C, Montini GC, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M.

Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):258-61. doi: 10.3816/CLML.2010.n.054.

PMID:
20709661
44.

Hairy cell leukemia: evaluation of the long-term outcome in 121 patients.

Zinzani PL, Pellegrini C, Stefoni V, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M.

Cancer. 2010 Oct 15;116(20):4788-92. doi: 10.1002/cncr.25243.

45.

Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.

Zinzani PL, Rossi G, Franceschetti S, Botto B, Di Rocco A, Cabras MG, Petti MC, Stefoni V, Broccoli A, Fanti S, Pellegrini C, Montini GC, Gandolfi L, Derenzini E, Argnani L, Fina M, Tucci A, Bottelli C, Pileri S, Baccarani M.

Clin Cancer Res. 2010 Aug 1;16(15):3998-4004. doi: 10.1158/1078-0432.CCR-10-0162. Epub 2010 Jun 11.

46.

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M.

Ann Oncol. 2010 Apr;21(4):860-3. doi: 10.1093/annonc/mdp508. Epub 2009 Nov 3.

PMID:
19887465
47.

MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients.

Derenzini E, Fina MP, Stefoni V, Pellegrini C, Venturini F, Broccoli A, Gandolfi L, Pileri S, Fanti S, Lopci E, Castellucci P, Agostinelli C, Baccarani M, Zinzani PL.

Ann Oncol. 2010 Jun;21(6):1173-8. doi: 10.1093/annonc/mdp455. Epub 2009 Oct 27.

PMID:
19861578
48.

Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.

Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M.

Clin Lymphoma Myeloma. 2009 Oct;9(5):381-5. doi: 10.3816/CLM.2009.n.074.

PMID:
19858058
49.

Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma.

Maffione AM, Castellucci P, Stefoni V, Nanni C, Tani M, Rubello D, Ambrosini V, Zinzani P, Franchi R, Fanti S.

Clin Nucl Med. 2009 Nov;34(11):777-8. doi: 10.1097/RLU.0b013e3181b81c34.

PMID:
19851173
50.

Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.

Derenzini E, Stefoni V, Pellegrini C, Fina MP, Broccoli A, Venturini F, Gandolfi L, Pileri SA, Martelli M, Petti MC, Perrotti A, De Renzo A, Zaja F, Baccarani M, Zinzani PL.

Leuk Lymphoma. 2009 Nov;50(11):1824-9. doi: 10.3109/10428190903216796.

PMID:
19814687

Supplemental Content

Loading ...
Support Center